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Summary
1. In higher eukaryotes, metabolism and immunity
are tightly coupled. However, whereas in evolutionary
terms, a compromised immune response due to
undernourishment has been the predominant problem, the
inflammatory response to obesity and other life style-
associated diseases has increased in relevance in Western
societies in the last hundred years.
2. Traditionally, fat tissue has been considered as the
major source of pro-inflammatory secreted factors in these
pathologies. In recent years however, the contribution of
other tissues to a disease-causing chronic inflammation has
been increasingly appreciated.
3. The peroxisome proliferator-activated receptor γ
coactivator 1α (PGC-1α) is one of the key regulatory
factors in the active skeletal muscle. Aberrant expression of
PGC-1α in inactive muscle fibres could link a sedentary life
style, persistent systemic inflammation and the higher risk
for many chronic diseases. Modulation of PGC-1α activity
in skeletal muscle might accordingly have a broad
therapeutic effect. Here, recent advances in the
understanding of the role of muscle PGC-1α in health and
disease are reviewed.
Introduction
Multicellular organisms depend on the ability to store
energy for times of famine and to fight infections.1,2 The
immune response is very energy demanding and therefore,
inflammatory processes strongly inhibit anabolic processes
such as those controlled by insulin signaling. For example,
fever boosts energy consumption by 7-13% per 1°C
increase in body temperature, sepsis even by 30-60%.3 On
the other hand, an undernourished state is
immunosuppressive, as observed in malnourished or
starving individuals with an increased susceptibility for
infectious diseases. Accordingly, the molecular systems
regulating metabolic processes and immune response have
co-evolved and mutually regulate each other.4 In lower
organisms like the common fruit fly Drosophila
melanogaster, metabolic and immune processes are even
associated with one organ, the fat body, whereas in higher
organisms, a deeper specialization of tissues occurred.
Nevertheless, even in humans, metabolic organs are often
closely linked with immune cells or have intrinsic
immunomodulatory functions. For example, in the liver,
hepatocytes are located adjacent to Kupffer cells, and
macrophages are in close contact to adipocytes in fat.1,2,4
In the past 100 years, physical activity and food
intake patterns have changed drastically in Western
countries. Concomitant with this shift in energy
metabolism, the incidence rates for obesity, type 2 diabetes,
cardiovascular disease, hypertension and other life style-
associated pathologies have reached epidemic
proportions.5,6 Thus, in contrast to the previous 250,000
years when Homo sapiens mainly struggled with a lack of
food, we now pay the price for an abundance of energy-rich
food and the decreased importance of physical activity in
daily life. Like malnutrition, overnutrition is linked to
pathological changes in immune function, however in the
diametrically opposite way. In contrast to the
immunosuppression in undernourished individuals, the
dysbalance between energy intake and dissipation triggered
by overnutrition leads to a persistent, low-grade
inflammatory state and an increased susceptibility to
chronic diseases.2,4 Importantly, this chronic inflammation
is different from the classic immune response to an
infectious agent and thus has been referred to as meta- or
para-inflammation.2,4 However, the same organs at the
intersection of metabolism and immune function are
involved in precipitating all of these different inflammatory
responses.7
Adipose tissue is a major driver of inflammation in
obesity
Excess energy is mostly stored in adipose tissue
where adipocytes become enlarged, ultimately resulting in
obesity. In addition to energy storage, fat is an important
endocrine organ and accordingly secretes a number of
hormones that regulate systemic energy homeostasis and
appetite.8-10 In an obese individual, adipocytes are also a
major source of pro-inflammatory cytokines and other
detrimental factors.10,11 Gökhan Hotamisligil, Bruce M.
Spiegelman and colleagues described the production and
secretion of the tumor necrosis factor α (TNFα) by fat
tissue in 1993 and thereby provided the first link between
obesity, inflammation and insulin resistance.12 In the
meantime, numerous other adipose-derived pro-
inflammatory proteins, members of the “adipokine” family,
have been identified.11,13 Once released, many of these
hormones promote insulin resistance in other peripheral
tissues. Thus, an inflammatory response from adipose tissue
and to a lesser extent from the liver triggers early, disease-
causing events in obesity.
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Figure 1. Myokine production and the inflammatory state in skeletal muscle. Myokines secreted by an active muscle
might contribute to the systemic beneficial effects of exercise. Reduced muscle activity is associated with impaired PGC-1α
expression. A number of pro-inflammatory cytokines are elevated in individuals with inadequate physical activity. This per-
sistent, low-grade inflammation could subsequently increase the risk for a number of chronic diseases. In contrast, extreme
performances and the accompanying fibre damage result in a state of temporary immunosuppression.
Skeletal muscle as an endocrine organ
Although an increased production of TNFα in
skeletal muscle of obese patients was reported in 1996,14
skeletal muscle as a significant contributor to chronic
inflammation in metabolic diseases has been neglected for
years. This is surprising since skeletal muscle makes up
around 40% of body weight and is the largest storage site
for glucose in the form of glycogen. Moreover, in a healthy
organism, muscle tissue is very sensitive to insulin and the
developing insulin resistance of this tissue contributes
significantly to the etiology of type 2 diabetes.15,16 Finally, a
sedentary life-style is a strong and independent risk factor
for many chronic diseases, including those that are
associated with persistent, systemic inflammation.17 For
example, lack of adequate physical activity is linked to type
2 diabetes, obesity, cardiovascular diseases, certain cancers,
neurodegeneration, musculoskeletal disorders and other
pathologies, thereby increasing morbidity and mortality and
reducing the quality of life as well as overall life
expectancy.17 In contrast, exercise, even in the absence of
significant weight loss, is an excellent preventative and
therapeutic intervention for many chronic disorders.18 For
example, changes in life-style that consist of diet and
exercise, rival or even exceed currently prescribed drugs in
terms of therapeutic efficacy against type 2 diabetes.19
In recent years, factors produced and secreted by the
contracting muscle fibres have been found and termed
“myokines”, analogous to the adipokines that are released
from fat.20,21 Interestingly, many myokines have a complex
expression pattern and exert beneficial and detrimental
effects, respectively, depending on the cellular
context.20,22,23 For example, short-lived pulses of
interleukin-6 (IL-6), IL-8 and IL-15 are elicited by
moderate exercise bouts and could mediate some of the
systemic effects of physical activity (Figure 1).24,25 In
contrast, persistent elevation of IL-6 is strongly associated
with obesity and type 2 diabetes.4 Thus, depending on the
secretion pattern and the cellular context, IL-6 might
mediate pro- or anti-inflammatory effects.23 Very high-
intensity exercise paradigms are accompanied with the
elevation of a specific set of cytokines that includes IL-6
and the unequivocally pro-inflammatory TNFα20,26 In that
context, these myokines most likely contribute to the
immunocompromised and inflammatory state that is
observed after extreme physical activity.26
PGC-1α regulates muscle fibre plasticity
Exercise triggers major phenotypic adaptations in
skeletal muscle. This biological program is predominantly
regulated by changes in gene transcription.27 Importantly,
molecular changes in myofibres differ between the acute
adaptations to individual bouts of exercise and those
observed in a chronically trained muscle. In both cases
however, similar signaling pathways are responsible for
initiating the adaptations. Motor neuron activation of
muscle fibres results in an elevation of intracellular calcium
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Figure 2. Regulation and function of PGC-1α in skeletal muscle fibres. All major signaling pathways that are activated
in an active muscle fibre converge on the PGC-1α promoter, the protein or both. In turn, PGC-1α initiates the adaptations
of muscle to physical activity by regulating metabolic, myofibrillar and neuromuscular junction-specific genes.
levels.28-30 Increased energy metabolism and hence ATP
consumption shifts the ATP to AMP ratio and thereby
activates the AMP-dependent protein kinase (AMPK).31,32
At the same time, an altered NAD+ to NADH ratio alters
the activity of the silencing information regulator
2-ortholog SIRT1.33-35 The cellular stress associated with
fibre contraction leads to an increased activity of the p38
mitogen-activated protein kinase (p38 MAPK) and the
production of nitric oxide (NO).36,37 Hormonal changes
elicited by the fight-or-flight reaction to physical activity
include elevated levels of β-adrenergic agonists, some of
which bind to β2-adrenoreceptors on the surface of muscle
fibres.27,38-40 Finally, the exercise-induced synaptic
remodeling of the neuromuscular junction (NMJ) are
initiated and maintained by motor neuron-released
paracrine factors that act on muscle.41-43 Importantly, all of
these signaling pathways converge on the peroxisome
proliferator-activated receptor γ coactivator 1α (PGC-1α)
resulting in either a transcriptional induction, alteration of
protein activity, or both (Figure 2).44,45 In turn, by binding
to a diverse set of transcription factors, PGC-1α regulates
many, if not all of the adaptations of the muscle fibre to
endurance exercise.44,45 First and foremost, PGC-1α
increases mitochondrial biogenesis and function.46
Accordingly, fatty acid β-oxidation, oxidative
phosphorylation and ATP production are augmented.47-49
Then, the set of myofibrillar genes prototypical for the slow
twitch, high endurance type I and IIa muscle fibres is
induced by PGC-1α50 Furthermore, the expression of the
ubiquitine ligases that promote protein degradation and
fibre atrophy in an inactive muscle is reduced.51 Finally, the
transcriptional rate of genes encoding postsynaptic NMJ
proteins is altered in synaptic nuclei.41 Accordingly, ectopic
expression of PGC-1α in skeletal muscle is sufficient to
promote a fibre-type shift towards a higher proportion of
oxidative muscle fibres and thereby evoke a trained
phenotype in the mouse model.50,52 By inducing the
biological program for exercise, elevation of PGC-1α ev en
prevents disuse-induced fibre atrophy,51 blunts the
detrimental side-effects of statin drugs in muscle,53
ameliorates Duchenne muscular dystrophy,41 and a form of
a mitochondrial myopathy54 in the respective animal
models.
Pathological consequences of PGC-1α dysregulation in
muscle
In humans, a tight correlation between the relative
levels of physical activity and PGC-1α has been observed
(e.g., Russell et al., 200355). PGC-1α expression is
transiently elevated after each bout of endurance exercise,
similar to the expression pattern described for IL-6.
However, a causal link between the expression patterns of
PGC-1α and IL-6 is unclear. In a chronically trained
muscle, basal levels of PGC-1α are higher than those
observed in an untrained individual,55 yet a superimposed
pulsative regulation of PGC-1α expression following each
exercise bout is maintained.56 In contrast, aberrantly low
PGC-1α levels are found in the muscle of sedentary
individuals and type 2 diabetic patients, at least in some
populations.57,58 It is unknown how much this dysregulation
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contributes to the etiology and pathology of this disease.
However, a significant contribution of PGC-1α on glucose
homeostasis is implied by the results from muscle-specific
knockout mouse models. Mirroring the data from PGC-1α
muscle transgenic mice,50 PGC-1α muscle-specific
knockout animals exhibit a higher number of glycolytic
type IIx and IIb fibres concomitant with a reduction in
mitochondrial gene expression and oxidative capacity.59,60
As a consequence, these mice are hypoactive and restricted
in their ability to exercise.59,60 Moreover, whole body
glucose and insulin homeostases are abnormally
regulated.60 These findings confirm the important role for
PGC-1α in metabolic and myofibrillar plasticity of muscle
fibres. Surprisingly though, PGC-1α muscle-specific
knockout animals reveal signs of muscle damage as
revealed by an increase in plasma creatine kinase levels and
the number of perforated fibres in histological stainings.59
Whereas this fibre damage is limited in sedentary animals,
the myopathy is exacerbated by physical activity.59 Thus,
physiological levels of PGC-1α seem essential for normal
muscle fibre integrity.
Increased inflammation could link PGC-1α to muscle
fibre damage
It is unclear how fibre damage is triggered in muscle-
specific PGC-1α knockout animals. Similarly, the
molecular mechanisms that underlie the therapeutic effects
of PGC-1α in different muscle diseases are unknown,
although several candidate mechanisms have been
suggested.61 Intriguingly, pro-inflammatory markers are
elevated in mice with an ablated PGC-1α gene in
muscle.59,60 In addition to the local inflammatory reaction
in skeletal muscle, PGC-1α muscle-specific knockout
animals exhibit higher levels of circulating TNFα and
IL-6.59,60 Inflammation contributes to fibre damage and
muscle wasting in a variety of different muscle
diseases.62-64 Whether the inflammation in PGC-1α muscle-
specific knockout mice is cause or consequence of the fibre
damage has not been elucidated. For example, PGC-1α
might directly modulate inflammatory gene expression, e.g.,
by altering reactive oxygen species in muscle, or the
inflammation could be secondary to fibre damage and the
subsequent removal of the debris. In any case however, the
elevation of circulating pro-inflammatory factors and hence
the systemic inflammatory state seems sufficient to link
dysregulated muscle function to pathologies in other organs
such as the deficient insulin secretion from pancreatic β
cells in these animals.60
Conclusions
Chronic systemic inflammation is associated with an
increased risk for many diseases. In addition, exercise has
health benefits on the whole body, not just skeletal muscle.
Thus, intrinsic adaptations in muscle fibres and the
consequent distal signaling, most likely by hormonal or
neuronal pathways, must mediate the crosstalk between
active muscles and other organs. Reduction of PGC-1α
levels and the subsequent systemic elevation of pro-
inflammatory cytokines might be the elusive link between a
sedentary life-style and the increased risk for chronic
diseases (Figure 1).61 Accordingly, a pharmacological
modulation of PGC-1α in muscle might have therapeutic
benefits beyond that tissue. Unfortunately, despite various
efforts, such compounds that robustly alter PGC-1α gene
expression in skeletal muscle and not other tissues with
potential detrimental side effects, and which can be safely
and chronically used in patients remain elusive.65,66 Thus,
as long as the inherent limitations of targeting a coactivator
protein have not been overcome, a healthy life-style
remains the best remedy against chronic diseases.
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